Saturday, December 27, 2014 Last update: 6:33 AM
FreshNews.com - Covering Large & Obscure Tech Companies Since 1996

Neurocrine Biosciences, Inc.

News articles for Neurocrine Biosciences, Inc.:

Wednesday, December 10, 2014

  • Neurocrine Biosciences Announces Expansion of its Clinical Pipeline
    SAN DIEGO, Dec. 10, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has entered clinical trials for the treatment of classic congenital adrenal hyperplasia (CAH) a disease that affects approximately 20,000-30,000 people ... read more

Thursday, December 4, 2014

Tuesday, November 25, 2014

Wednesday, November 12, 2014

Tuesday, November 4, 2014

Monday, November 3, 2014

  • Neurocrine Biosciences to Present at the Nomura Biotechnology Conference
    SAN DIEGO, Nov. 3, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Nomura Biotechnology Conference in Boston. The live presentation takes place on Thursday, November 6 ... read more
  • Neurocrine Biosciences Reports Third Quarter 2014 Results
    SAN DIEGO, Nov. 3, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended September 30, 2014. For the third quarter of 2014, the Company reported a net loss of $15.9 million, or $0.21 loss per share, ... read more

Thursday, October 30, 2014

Monday, October 27, 2014

Monday, October 20, 2014

Thursday, October 2, 2014

Wednesday, October 1, 2014

Wednesday, September 3, 2014

Wednesday, August 6, 2014

  • Neurocrine Biosciences Reports Second Quarter 2014 Results
    SAN DIEGO, Aug. 6, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended June 30, 2014. For the second quarter of 2014, the Company reported a net loss of $13.4 million, or $0.18 loss per share, compared ... read more